WuXi Biologics to Invest $60 Million in New Singapore Biomanufacturing Facility

Published on: 

WuXi Biologics will build a biologics manufacturing facility in Singapore that will use both fed-batch and continuous perfusion-based single-use bioreactors.

WuXi Biologics announced on May 22, 2018 that it will invest S$80 million (approximately US$60 million) and hire approximately 150 employees to establish a biologics manufacturing facility in Singapore. The facility will be the company’s tenth global drug substance manufacturing facility, its second site outside of China, and its first in Asia outside of China. The company is headquartered in Wuxi city, Jiangsu province, China. 

This “facility of the future” will be built upon a new approach WuXi Biologics has pioneered deploying single-use bioreactors. A total of approximately 4500-L bioreactor capacity will be installed with two, 2000-L traditional fed-batch and one, 500-L perfusion-based continuous processing bioreactors. The facility will be able to handle both clinical and small-volume commercial production. The company will also build an early-stage bioprocess development laboratory.

“Singapore is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global biomanufacturing network to ensure that biologics are manufactured at the highest quality and with a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. With the strong support, we believe we can quickly push forward this exciting project,” said Dr. Ge Li, chairman of WuXi Biologics, in the press release.


Source: WuXi Biologics